Revvity RVTY Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Segment revenue by Business | ||||||
| Diagnostics | $349.27M+7.7% | $390.07M+10.0% | $356.13M+3.2% | $354.39M+3.3% | $324.37M+3.5% | |
| Life Sciences | $361.85M+6.3% | $381.99M+1.9% | $342.82M+1.2% | $365.9M+5.0% | $340.4M+1.2% | |
| Segment Cost of Revenue by Business | ||||||
| Diagnostics | $156.75M+16.0% | $183.64M+19.0% | $158.9M+9.8% | $156.04M+6.7% | $135.19M+3.1% | |
| Life Sciences | $131.57M+10.3% | $131.97M+4.2% | $129.98M+10.6% | $135.03M+12.1% | $119.32M-3.4% | |
| Segment operating income by Business | ||||||
| Diagnostics | $76.12M+2.8% | $91.35M+0.2% | $89.38M-4.8% | $89.42M-3.6% | $74.02M-2.9% | |
| Life Sciences | $103.98M-1.6% | $136.03M-1.6% | $101.05M-8.6% | $115.47M-1.8% | $105.71M+4.7% | |
| Segment research and development expenses by Business | ||||||
| Diagnostics | $26.21M+3.7% | $30.38M+33.1% | $23.13M+2.2% | $24.8M+17.8% | $25.27M+7.5% | |
| Life Sciences | $31.62M+11.9% | $27.74M+5.8% | $27.61M+7.2% | $28.42M+7.8% | $28.27M+8.5% | |
| Segment Selling, general and administrative expenses by Business | ||||||
| Diagnostics | $90.19M+0.3% | $84.69M-1.9% | $84.72M+0.7% | $84.13M+1.3% | $89.89M+8.8% | |
| Life Sciences | $94.67M+8.7% | $86.25M+3.0% | $84.19M-0.9% | $86.99M+3.3% | $87.09M+1.3% | |
| Restructuring and Other Costs (Income) by Business | ||||||
| Diagnostics | $7.55M+5,496% | —— | —— | —— | $135K-95.7% | |
| Life Sciences | $3.23M+27.7% | —— | —— | —— | $2.53M+123% | |
| Foreign currency translation by Business | ||||||
| Diagnostics | -$9.83M-169% | $3.63M— | $0— | $30.78M— | $14.24M+261% | |
| Life Sciences | -$24.95M-174% | $9.23M+114% | $0-100% | $72.72M+1,595% | $33.63M+262% | |
| Goodwill by Business | ||||||
| Diagnostics | $1.86B-4.0% | $1.87B-2.8% | $1.96B— | $1.97B— | $1.94B— | |
| Life Sciences | $4.75B+3.9% | $4.74B+4.5% | $4.64B— | $4.65B— | $4.58B— | |
| Goodwill, Acquisition by Business | ||||||
| Diagnostics | $0— | —— | —— | —— | —— | |
| Life Sciences | $32.04M— | —— | —— | —— | —— | |
| Depreciation by Business | ||||||
| Diagnostics | $9.56M+39.6% | $9.49M-17.7% | $8.79M-0.6% | $8.28M+3.5% | $6.85M-11.1% | |
| Life Sciences | $9.91M+37.9% | $9.3M+83.7% | $8.46M-2.5% | $8.55M+5.2% | $7.19M-13.1% | |
| Lease Abandonment Charges Included In Restructuring and Other Costs by Business | ||||||
| Diagnostics | $1.2M+500% | $200K— | $200K— | $200K— | $200K— | |
| Life Sciences | $1.3M-16.1% | $1.55M— | $1.55M— | $1.55M— | $1.55M— | |
| Segment revenue by Geography | ||||||
| Americas | $315.99M+3.7% | $320.48M+0.6% | $307.28M+1.6% | $323.58M+5.1% | $304.63M+3.5% | |
| Asia | $172.08M-3.5% | $214.42M+0.5% | $189.28M-5.2% | $193.07M-3.1% | $178.34M+0.8% | |
| Europe | $223.05M+22.7% | $237.16M+20.1% | $202.4M+11.2% | $203.63M+10.3% | $181.79M+1.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Revvity break its business down?
- Revvity (RVTY) reports segment revenue by business across 2 parts — Diagnostics and Life Sciences. Each is extracted from the segment footnotes and tracked over time.
- Where does Revvity's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Revvity's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
